Use of High Dose Cyclophosphamide in Combination with Anti-Idiotypic Vaccines in Anti-cancer Therapy
Recently, immunotherapy based techniques have been developed for the treatment of various cancers. The central premise underlying immunotherapy for cancer is the presence of antigens which are selectively or abundantly expressed or mutated in cancer cells. Despite advances in the development of various immune therapies for treatment of cancer, immune tolerance presents a major barrier. Therefore, there is a need to identify therapies or agents which may be used to break immune tolerance which severely limits the use of various immune therapies in cancer therapy. Researchers at JHU have discovered that high-dose cyclophosphamide is effective in breaking immune tolerance; an obstacle in the use of various immune-based therapeutics for cancer. The present invention provides methods of treating various cancers and, in particular, B-cell derived cancers, such as non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma or multiple myeloma, using high-dose pulsed amount of the oxazaphosphorine drug cyclophosphamide, in combination with an immune therapeutic such as an autologous anti-idiotypic vaccine. Description (Set) Proposed Use (Set) High dose cyclophosphamide may be used as a combination therapy with an immune therapeutic such as an autologous anti-idiotypic vaccine in the treatment of cancer, especially blood cancers.Inventor(s): Brodsky, Robert A.
Type of Offer: Licensing
« More Medical Patents